RxDoctor Payments Data

Nestor Arita, MD

Vascular Surgery · Mountain Home, ARNPI 1124438072

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (51.3%), travel and lodging and education — rather than concentrated in one kind of arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.2%.

$19,360in general payments, 2019–2025

Across 187 payments — averaging $103.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • W. L. Gore & Associates, Inc.$4K
  • Silk Road Medical, Inc.$3K
  • Penumbra, Inc.$3K
  • Endologix LLC$3K
  • Abbott$2K
  • Bolton Medical Inc$2K
  • plus $4K from 22 others

What the payments were for

  • Travel & lodging$9,07647%
  • Food & beverage$9,93151%
  • Education$3542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few vascular surgery providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$71,446
Medicare patients
199
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban16$11,832
EliquisApixaban12$6,788
ClopidogrelClopidogrel Bisulfate40$345
Cilostazol20$229
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$169
Atorvastatin Calcium18$140
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen35$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$17$11,83216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few vascular surgery providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other vascular surgery in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →